Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema  Andrew A. Moshfeghi, MD, MBA, Howard Shapiro, PhD, Linda A. Lemmon, PharmD, MBA, Shamika Gune, MD  Ophthalmology Retina   DOI: 10.1016/j.oret.2017.05.003 Copyright © 2017 American Academy of Ophthalmology Terms and Conditions

Figure 1 Study design. BCVA = best-corrected visual acuity; RBZ = ranibizumab. Ophthalmology Retina  DOI: (10.1016/j.oret.2017.05.003) Copyright © 2017 American Academy of Ophthalmology Terms and Conditions

Figure 2 Percentage of phakic study eyes that underwent cataract surgery. ∗Surgeries that occurred in the sham arm between months 25 and 36 were not included in analyses because of crossover to ranibizumab 0.5 mg after month 24. †Excludes eyes that were pseudophakic at baseline. NA = not applicable. Ophthalmology Retina  DOI: (10.1016/j.oret.2017.05.003) Copyright © 2017 American Academy of Ophthalmology Terms and Conditions

Figure 3 Time to cataract surgery among phakic study eyes in RIDE/RISE. Ophthalmology Retina  DOI: (10.1016/j.oret.2017.05.003) Copyright © 2017 American Academy of Ophthalmology Terms and Conditions

Figure 4 Vision before and after cataract surgery in phakic study and fellow eyes of the sham and pooled ranibizumab groups. Error bars represent the 95% confidence intervals of the means. ∗Includes cataract surgeries through month 24 because of subsequent crossover to ranibizumab 0.5 mg. †Includes cataract surgeries through month 36. BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study. Ophthalmology Retina  DOI: (10.1016/j.oret.2017.05.003) Copyright © 2017 American Academy of Ophthalmology Terms and Conditions